Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Hao Xie, Alex Adjei

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.

Original languageEnglish (US)
Pages (from-to)358-376
Number of pages19
JournalJournal of Thoracic Oncology
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Thorax
Drug Therapy
Antibodies
Neoplasms
Pharmaceutical Preparations
Hematologic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Monoclonal Antibodies
Pharmacology
Breast Neoplasms
Antigens
Therapeutics

Keywords

  • Antibody
  • Conjugate
  • Thoracic malignancies
  • Toxophore

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. / Xie, Hao; Adjei, Alex.

In: Journal of Thoracic Oncology, Vol. 14, No. 3, 01.03.2019, p. 358-376.

Research output: Contribution to journalReview article

@article{413dc192e15f46fcabb685f8a7f4c507,
title = "Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies",
abstract = "Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.",
keywords = "Antibody, Conjugate, Thoracic malignancies, Toxophore",
author = "Hao Xie and Alex Adjei",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.jtho.2018.11.034",
language = "English (US)",
volume = "14",
pages = "358--376",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

AU - Xie, Hao

AU - Adjei, Alex

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.

AB - Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.

KW - Antibody

KW - Conjugate

KW - Thoracic malignancies

KW - Toxophore

UR - http://www.scopus.com/inward/record.url?scp=85061662820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061662820&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.11.034

DO - 10.1016/j.jtho.2018.11.034

M3 - Review article

VL - 14

SP - 358

EP - 376

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -